16 Oil and Gas Stocks to Sell Now

RSS Logo Portfolio Grader Popular Posts: 5 Biotechnology Stocks to Buy Now17 Oil and Gas Stocks to Sell Now4 Semiconductor Stocks to Buy Now Recent Posts: 16 Oil and Gas Stocks to Sell Now 12 “Triple F” Stocks to Sell 5 Stocks With Bad Analyst Earnings Revisions — BONT VRTX PSEM TRNX UEC View All Posts

The ratings of 16 Oil and Gas stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

PDC Energy’s (NASDAQ:) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. PDC is an oil and gas company with drilling and production operations in the Rocky Mountains, the Appalachian Basin, and Michigan. In Portfolio Grader’s specific subcategories of Earnings Revisions and Cash Flow, PETD also gets F’s. As of Sept. 27, 2013, 17.6% of outstanding PDC Energy shares were held short. .

EOG Resources, Inc. (NYSE:) gets weaker ratings this week as last week’s C drops to a D. EOG Resources is in the business of the exploration, development, production, and marketing of natural gas and crude oil. The stock gets F’s in Earnings Growth, Earnings Momentum, and Margin Growth. The trailing PE Ratio for the stock is 44.50. .

Suncor Energy’s (NYSE:) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Suncor Energy is an integrated energy company in Canada. The stock gets F’s in Earnings Momentum and Earnings Surprise. .

The rating of Enbridge Energy Partners, L.P. Class A (NYSE:) declines this week from a D to an F. Enbridge Energy Partners transports crude oil and natural gas liquids to refineries in the midwestern United States and eastern Canada. The stock receives F’s in Earnings Growth, Earnings Revisions, and Earnings Surprise. Cash Flow and Sales Growth also get F’s. The stock’s trailing PE Ratio is 27.40. .

This week, PVR Partners, L.P.’s (NYSE:) rating worsens to a D from the company’s C rating a week ago. Penn Virginia Resource Partners owns and operates a network of natural gas pipelines and processing plants which provide gathering, transportation, compression, processing, dehydration and related services to natural gas producers. .

This week, Green Plains Renewable Energy, Inc. (NASDAQ:) drops from a C to a D rating. Green Plains Renewable Energy constructs and operates dry mill, fuel-grade ethanol production facilities. The stock gets F’s in Earnings Growth, Earnings Revisions, and Margin Growth. As of Sept. 27, 2013, 11.3% of outstanding Green Plains Renewable Energy, Inc. shares were held short. .

Chevron Corporation’s (NYSE:) rating weakens this week, dropping to a D versus last week’s C. Chevron gives management and technological support to international subsidiaries that operate petroleum, chemicals, mining, power generation, and energy services. The stock also gets an F in Sales Growth. .

ONEOK Partners, L.P. (NYSE:) earns a D this week, falling from last week’s grade of C. ONEOK Partners is engaged in the gathering, processing, storage, and transportation of natural gas in the United States. The stock also gets an F in Sales Growth. .

Continental Resources, Inc. (NYSE:) earns an F this week, moving down from last week’s grade of D. Continental Resources explores for, develops, and produces oil and natural gas properties in the United States. The stock gets F’s in Earnings Growth, Earnings Momentum, Cash Flow, and Sales Growth. The stock currently has a trailing PE Ratio of 25.50. .

Slipping from a C to a D rating, Teekay Corporation (NYSE:) takes a hit this week. Teekay is a provider of international crude oil and petroleum product transportation services. The stock gets F’s in Earnings Momentum, Earnings Revisions, and Earnings Surprise. Equity and Cash Flow also get F’s. .

Frontline (NYSE:) experiences a ratings drop this week, going from last week’s D to an F. Frontline owns a fleet of very large crude carriers and Suezmax tankers that transport crude oil and oil products between ports. The stock receives F’s in Earnings Revisions, Equity, Cash Flow, and Sales Growth. As of Sept. 27, 2013, 13.3% of outstanding Frontline shares were held short. .

The rating of Endeavour International Corporation (NYSE:) slips from a D to an F. Endeavour International is an international oil and gas exploration and production company that acquires, explores, and develops energy reserves. The stock gets F’s in Equity and Cash Flow. As of Sept. 27, 2013, 22.3% of outstanding Endeavour International Corporation shares were held short. .

North European Oil Royalty Trust (NYSE:) is having a tough week. The company’s rating falls from a D to an F. North European Oil Royalty Trust is involved in gas and oil production. It holds overriding royalty rights in certain concessions or leases in the Federal Republic of Germany. The stock also gets an F in Sales Growth. The stock price has dropped 8.7% over the past month, worse than the 1.7% decrease the S&P 500 has seen over the same period of time. .

This is a rough week for SandRidge Energy, Inc. (NYSE:). The company’s rating falls to F from the previous week’s D. SandRidge Energy explores and produces natural gas and crude oil. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Margin Growth also get F’s. As of Sept. 27, 2013, 10.3% of outstanding SandRidge Energy, Inc. shares were held short. .

Gevo (NASDAQ:) gets weaker ratings this week as last week’s D drops to an F. Gevo operates as a technology development company for biobutanol. The stock gets F’s in Equity, Cash Flow, and Sales Growth. As of Sept. 27, 2013, 16.8% of outstanding Gevo shares were held short. .

Teekay Offshore Partners L.P. (NYSE:) earns a D this week, falling from last week’s grade of C. Teekay Offshore Partners LP provides marine transportation and storage services to the offshore oil industry. The stock also gets an F in Sales Growth. .

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.

3 Biotech Stocks Under $10 Making Big Moves

DELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.

>>5 Big Trades to Take Right Now

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

>>5 Bargain Bin Stocks to Buy This Fall

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside recently.

Synta Pharmaceuticals

Synta Pharmaceuticals (SNTA) is a biopharmaceutical company engaged in discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions such as cancer and chronic inflammatory diseases. This stock closed up 6.5% to $6.53 in Thursday's trading session.

Thursday's Range: $6.17-$6.64

52-Week Range: $3.76-$11.88

Thursday's Volume: 1.02 million

Three-Month Average Volume: 1.79 million

>>5 Stocks Spiking on Big Volume

From a technical perspective, SNTA bounced sharply higher here right off its 50-day moving average of $6.26 with decent upside volume. This stock recently pulled back from its high of $7.30 to its low of $5.90. Shares of SNTA are now starting to move back above its 50-day and within range of triggering a near-term breakout trade. That trade will hit if SNTA manages to take out some key overhead resistance levels at $7.30 to $7.85 with high volume.

Traders should now look for long-biased trades in SNTA as long as it's trending above its 50-day at $6.26 or above support at $5.90 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.79 million shares. If that breakout hits soon, then SNTA will set up to re-test or possibly take out its next major overhead resistance levels at $8.25 to $9.

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals (BCRX) is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. This stock closed up 3.4% to $7.24 in Thursday's trading session.

Thursday's Range: $6.96-$7.25

52-Week Range: $1.08-$7.41

Thursday's Volume: 1.39 million

Three-Month Average Volume: 2.51 million

>>5 Rocket Stocks to Buy for September Gains

From a technical perspective, BCRX jumped higher here with lighter-than-average volume. This stock has been trending sideways and consolidating for the last month and change, with shares moving between $6.07 on the downside and $7.41 on the upside. Shares of BCRX are now quickly moving within range of triggering a breakout trade above the upper-end of its recent sideways trading chart pattern. That trade will hit if BCRX manages to take out Thursday's high at $7.25 and its 52-week high at $7.41 with high volume.

Traders should now look for long-biased trades in BCRX as long as it's trending above some near-term support at $6.50 or at $6.07, and then once it sustains a move or close above those breakout levels with volume that hits near or above 2.51 million shares. If that breakout hits soon, then BCRX will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $9 to $10.

Cardium Therapeutics

Cardium Therapeutics (CXM) is a medical technology company mainly develops and commercializes novel products and devices for cardiovascular and ischemic disease, wound healing and tissue repair. This stock closed up 1.1% to $1.80 in Thursday's trading session.

Thursday's Range: $0.72-$0.84

52-Week Range: $0.58-$4.80

Thursday's Volume: 261,021

Three-Month Average Volume: 68,300

>>5 Stocks With Big Insider Buying

From a technical perspective, CXM bounced sharply higher here right off some near-term support at 72 cents with strong upside volume. This stock recently formed a double bottom chart pattern at 69 cents to 70 cents. Following that bottom, shares of CXM have started to rebound higher and move within range of triggering a major breakout trade. That trade will hit if CXM manages to take out some near-term overhead resistance levels at 86 cents to 92 cents, and then 96 cents with high volume.

Traders should now look for long-biased trades in CXM as long as it's trending above support at 70 cents and then once it sustains a move or close above those breakout levels with volume that hits near or above 68,300 shares. If that breakout hits soon, then CXM will set up to re-test or possibly take out its next major overhead resistance levels at $1.35.

To see more stocks that are making notable moves higher today, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.


RELATED LINKS:



>>5 Stocks Under $10 Set to Soar



>>4 Stocks Rising on Unusual Volume



>>5 Toxic Stocks You Should Sell

Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including

CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.


Index funds tell the tale of 2013’s winners

Many of life's rules are unchanging. Don't make toast in the bathtub. Let sleeping bears lie. Not one of your Facebook friends cares what you had for lunch.

But many financial rules change, and often not in a good way. For example, investing in an index fund is a fine idea. This was swell advice when there were only a few index funds.

Thanks to the ever-increasing need of the fund industry to attract new money, however, you now have hundreds of index funds from which to choose. Some of them are good. Some of them are awful. But it's no longer an easy decision, as you'll soon discover from third-quarter results.

Index funds dump the manager and instead follow an index, such as the Standard & Poor's 500, a large-company stock index, or the Russell 2000, a measure of small-company stock performance. Following an index has three distinct advantages:

• They eliminate the manager, who can be wrong as often as he is right.

• They have much lower fees than actively managed funds, which can be an enormous advantage over the long term.

• They tend to have fewer and smaller capital gains distributions than actively managed funds, which boosts your after-tax performance.

The classic example is the Vanguard 500 Index fund, which has beaten 65% of funds in Morningstar's large-company blend category over the past decade — all at a cost of 0.17% a year, or $1.70 for every $1,000 managed.

From an investment management perspective, however, running an S&P 500 index fund has some severe drawbacks. The product has no discernable difference from fund company to fund company except expenses, with lower being better. (Despite this, a few fund companies have managed to produce truly awful S&P 500 funds, such as the Rydex S&P 500 C shares, which charges an astounding 2.3% a year in expenses. It's like buying salt for $60 an ounce.)

Rather than try to create a high-priced commodity product, however, many fund companies simply tried to create index funds! with a twist. The worst are the leveraged funds, which use futures and options to give you twice the gain and twice the pain of a traditional fund. These not only tend to be more expensive than traditional index funds, but far riskier.

Not to pick on Rydex — OK, we're picking on Rydex — but consider the Rydex Inverse S&P 500 2x Strategy fund, which charges a mind-melting 2.51% expense ratio, according to Morningstar, the Chicago investment trackers. When the S&P 500 rises 1% in a day, the fund is designed to fall 2%, and vice versa. The fund is down 28.6% this year.

Is it possible this fund could be useful to the average investor? Yes. It's also possible to be strangled by an orangutan. It's just not likely. And it's far more likely that the average person could use this fund at the wrong time — and, by trying to avoid a loss, pay a high price for making the wrong call.

Other bad index funds include this year's likely top performer, the Direxion Daily Gold Miners Bear 3X shares, which pledges to fall 3% every day an index of gold mining stocks rises 1%. The fund is up 106.1% this year, because gold mining, a dicey occupation at best, is an awful business when the price of gold is falling. You need this fund like you need mice.

Are there any index funds — aside from the plain vanilla ones mentioned earlier — that are worth investigating? Actually, there are.

• Equal-weighted funds. The S&P 500 is weighted by market capitalization, which is a stock's share price multiplied by the number of shares outstanding. By that measure, Apple is the largest stock in the universe, and it gets 2.54% of the Vanguard 500 Index fund's assets. By the same measure, Boeing gets 0.43% of the fund's assets. An equal-weighted fund puts the same amount of assets into each of the index's components.

A fund that's weighted by market cap tends to do best in a concentrated market — that is, when one stock or group of stocks excels. The Guggenheim Investments S&P 500! Equal We! ighted ETF (ticker: RSP) has gained 24.3% this year, outpacing the cap-weighted S&P 500. The main reason could well be Apple, which has lost 6.8% this year, including reinvested dividends.

Equal-weighting makes more sense for funds that follow the Nasdaq 100 stock index: Apple accounts for 12.1% of the popular PowerShares QQQ fund, up 21.3% this year. The Direxion Nadaq 100 Equal Weighted Index shares (QQQE) has gained 29.1%.

• Value and growth indexes. A value manager looks for beaten-up stocks that Wall Street hates, and waits for them to reach normal value. A growth manager looks for stocks with rapid earnings growth, selling them when they disappoint.

Value stocks tend to pay more in dividends and suffer less in bear markets than growth funds do. Growth funds tend to soar in hot bull markets. This year, value has been the place to be: Guggenheim Investments S&P 500 Pure Value ETF (RPV) has gained 31.1% this year, while its companion, Guggenheim Investments S&P 500 Pure Growth ETF, has gained 28.9%.

• Cap-based indexes. Small-company stocks typically fare better than larger ones, because they have more room to grow. This year was no exception: The iShares Russell 2000 ETF (IWO) soared 27.6% this year, and the iShares Russell 2000 Growth ETF (IWZ) jumped 32.1%.

• Buyback and dividend indexes. The Schwab U.S. Dividend Equity ETF includes only stocks that have increased their dividends regularly: It's up 22.2%. The PowerShares Buyback Achievers fund (PKW) invests in companies that actually buy back their stock and reduce the number of shares outstanding — which, in theory, should make remaining shares more valuable. The fund is up 32.2% this year.

For most investors, your basic aim should be getting exposure to stocks at a low cost, and broadly based index funds are the best bet. You could cover the world with the iShares MSCI World ETF (URTH, up 18%) for just 0.24% a year in expenses, or $2.40 per $1,000 invested. Tough to argue with that. If you ! do use mo! re exotic indexes, remember that their above-average performance may someday come with above-average risk.

Bond yields show selloff peaking until rates rise

bonds, bond yields, andrew richman, bernanke

As the U.S. bond market suffers its worst rout since 2009, the gauge that historically signals more pain for fixed-income investors is instead suggesting yields are near their peak.

The gap between two- and 10-year Treasury yields widened to 2.55 percentage points this month, double the median of 1.23 points since 1990 and approaching the record 2.93 points in February 2010, data compiled by Bloomberg show. The yield curve is steepening at the fastest pace since 2009 as the Federal Reserve signals its intent to keep the target interest rate for overnight loans between banks at about zero into 2015 while reducing the bond-buying economic stimulus that drove 10-year yields to the highest level in more than two years.

While the yield curve typically steepens when faster growth leads investors to demand more insulation from inflation, bond strategists say this time is different. After rising from this year's low of 1.61 percent on May 1 to 2.93 percent last week, the increase in 10-year yields will slow, with rates reaching 3.05 percent in the second quarter of next year, according to 63 economists in a Bloomberg News survey. Losses will be limited by an economy growing at half the post-World War II average and an inflation rate below the Fed's 2 percent target, they say.

Yield 'Artifact'

“I don't think the steepness of the curve is reflective of very bullish expectations for growth or great concern for inflation,” Wan-Chong Kung, who helps oversee more than $100 billion as a fund manager at Nuveen Asset Management in Minneapolis, said in an Aug. 21 telephone interview. “It's an artifact of the very accommodative monetary policy we continue to operate under.”

When the yield curve reached its record in February 2010, investors pushed the 10-year rate to 3.77 percent after the Fed restated its intention to withdrawal extraordinary stimulus measures as the economy strengthened.

The widest gap before the 2007 financial crisis was 2.86 percent in August 2003 as the Fed held its overnight rate at a then-record 1 percent while the economy lost jobs amid sluggish growth. The average spread in the 1980s was 0.48 percentage point, 0.88 percentage point in the 1990s and 1.06 percentage points from 2000 through 2008.Housing Slump

Yields on 10-year Treasuries reached 2.93 percent on Aug. 22, the highest since July 2011 as minutes of the Fed's last meeting showed policy makers supported slowing the pace of its bond purchases this year. The price of the benchmark 2.5 percent note due August 2023 rose 3/32, or 94 cents per $1,000 face value, to 97 9/32 last week, Bloomberg Bond Trader prices show.

While yields touched the high for the year, bonds ended the week with a rally after a Commerce Department report showed that sales of newly built homes declined 13.4 percent in July to a 394,000 annualized pace, the weakest since October.

The yield was 2.83 percent today as of 8:20 a.m. in New York.

This year's losses on Treasuries -- the Bloomberg U.S. Treasury Bond Index is down 3.6 percent -- will reverse by mid-2014 if the analyst survey proves correct. An investor buying $10 million of 10-year notes will earn about $160,000 after accounting for interest payments by June 30 even if yields rise to 3 percent.

Fed Chairman Ben S. Bernanke has said the central bank will keep its overnight lending rate at zero to 0.25 percent into 2015. That's anchoring two-year note yields, which in turn restrain 10-year securities.Taper Speculation

“Until such time as it's pretty clear that the Fed is actually going to raise interest rates, an additional sell-off” will likely be capped, Ira Jersey, an interest-rate strategist at Credit Suisse Group AG in New York, said in an Aug. 19 telephone interview. The firm is one of the 21 primary dealers of U.S. government securities that trade with the Fed.

Speculation that the Fed will taper its $85 billion of monthly bond purchases led to the rout in bond markets, with Treasuries losing 3.6 percent this year.

The decline is the worst since the 3.72 percent loss in all of 2009 and more than the 3.35 percent drop in 1994 after the Fed doubled its benchmark rate to 6 percent, according to the Bank of America Merrill Lynch U.S. Treasury index. The firm's Global Broad Market Index has fallen 1.62 percent this year, the largest decline in data going back to 1997.

U.S.-registered bond mutual and exchange-traded funds lost $30.3 billion to investor redemptions this month through Aug. 19, the third-highest on record, according to a report last week by TrimTabs Investment Research in Sausalito, California. The withdrawals followed $69.1 billion of redemptions in June and $42 billion in October 2008.Yield 'Pressure'

“We are seeing retail bail out of bond funds,” Andrew Richman, the West Palm Beach, Florida-based director of fixed- income at SunTrust Bank's private wealth management division, which oversees about $101 billion, said in an Aug. 21 telephone interview. “The Fed is going to slow down their bond purchases. Foreign investors are also slowing down their bond purchases. And banks are actually dumping some Treasuries and making more loans. All of that is really putting pressure on yields.”

Bank holdings of Treasury and agency debt fell $34.7 billion to $1.81 trillion in July, the biggest monthly drop in 10 years, and an additional $20 billion in the first week of August, Fed data showed on Aug. 16. Commercial and industrial loans at U.S. banks have surged to $1.57 trillion, the highest since 2008, from $1.49 trillion in December, Fed data show.Bond Hedges

U.S. government securities held by international investors fell 2.2 percent to $5.6 trillion in June, and is down from the peak of $5.72 trillion in March, Treasury data show.

Traders are also selling Treasuries to hedge stakes in corporate and mortgage debt, John Briggs, a U.S. government bond strategist at RBS Securities Inc. in Stamford, Connecticut, said in an Aug. 20 telephone interview. RBS is also a primary dealer.

Fed policy makers were “broadly comfortable” with Bernanke's plan to start reducing bond buying, known as quantitative easing, this year if the economy improves, with a few saying tapering might be needed soon, according to the record of the Federal Open Market Committee's July 30-31 gathering released Aug. 21.

Reductions will be announced at the next FOMC meeting Sept. 17-18, according to 65 percent of economists in a Bloomberg survey conducted Aug. 9-13. Last month, 50 percent of respondents predicted a September reduction.

Bloomberg News Like what you've read?

77元住五星级大床房

 
  成为7天会员
¥77入住享受五星级大床房,全国1500多家分店任你选!
 
 

邮件无法正常显示请点击此处

7天连锁酒店秉承让顾客"天天睡好觉"的愿景,致力为注重价值的商旅客人提供干净、环保、舒适、安全的住宿服务,满足客户核心的住宿需求,7天连锁酒店集团酒店预订已建立覆盖全国超过1200家分店的经济型快捷连锁酒店网络,完善的酒店预订系统,让您预订酒店客房更加轻松快捷,是您出差、旅游好选择。

Kythera Biopharmaceuticals (KYTH): If You Missed the Double Chin Rally, Try Small Caps ZLTQ, SLTM & CYNO

On Tuesday, small cap biotech stock Kythera Biopharmaceuticals Inc (NASDAQ: KYTH) surged around 25% after announcing that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints for the reduction of so-called double chins; but if investors missed out on that rally, small caps Zeltiq Aesthetics Inc (NASDAQ: ZLTQ), Solta Medical Inc (NASDAQ: SLTM) and Cynosure, Inc (NASDAQ: CYNO) each have a piece of the aesthetic market as well. In the case of Kythera Biopharmaceuticals, its ATX-101 can be injected to deal with double chins – meaning its less invasive than liposuction as the drug dissolves fat cells but leaves other tissue alone. JP Morgan has noted:

With positive data now in-hand,we see a very high probability of a 2015 approval for ATX101 in the US and Europe in what we see as a $500+ million annual sales opportunity to Kythera.We reiterate our Overweight rating and our raising our price target to $45 from $34.

However, Kythera Biopharmaceuticals is not the only small cap targeting the aesthetic treatment market as investors might want to consider the following stocks: 

Zeltiq Aesthetics Inc. Focused on the design, development and commercialization of non-invasive procedures for the reduction of unwanted fat tissue, small cap Zeltiq Aesthetics' first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat that may not respond to diet or exercise. On Tuesday morning, Zeltiq Aesthetics held an investor day and afterwards the stock jumped from the $8.30 level to the $9.30 level as investors must have liked what they heard (you can listen and view the presentation by clicking here). The PowerPoint presentation noted that treating existing aesthetic patients is a $11 billion market in the US (14.6 million procedures with 40 - 54 year olds making up 48% of the procedures) and that there are 30,000 aesthetic practices globally with the company initially targeting 5,000 of these accounts and currently having about 1,500 accounts – meaning there is still a large untapped market. Otherwise, investors should note that the last time Zeltiq Aesthetics reported earnings, it reported an 18% year-over-year increase and a 32% sequential increase to $26.3 million along with a net loss of $3.6 million verses $8.1 million. On Wednesday, Zeltiq Aesthetics fell 0.64% to $9.25 (ZLTQ has a 52 week trading range of $3.20 to $9.69 a share) for a market cap of $334.46 million plus the stock is up 106.5% since the start of the year, up 53.4% over the past year and down 40.8% since October 2011. 

Solta Medical Inc. Focused on the medical aesthetics market, small cap Solta Medical offers aesthetic energy devices for skin resurfacing and rejuvenation, acne reduction, body contouring and skin tightening, as well as tools and accessories to optimize the latest liposuction techniques. At the beginning of September, Solta Medical announced the appointment of an executive search firm to find a permanent President and Chief Executive Officer after the resignation of Stephen J. Fanning on August 6, 2013. He resigned after Solta Medical reported "dismal" earnings or rather a dismal guidance. Specifically, Solta Medical reported a 16% revenue increase to $43.2 million along with GAAP net income of $3.8 million verses a GAAP net loss of $26.3 million. However, Solta Medical gave a full year revenue guidance of approximately $165 million verses $180 million while Non-GAAP operating income guidance was lowered from $13 million to $16 million to approximately $10 million. Roth Capital Partners analyst Chris Lewis issued a research note which said the company will continue to face challenges from pricing pressure, management uncertainties and sales force turnover. On Wednesday, Solta Medical rose 1.41% to $2.16 (SLTM has a 52 week trading range of $1.44 to $3.21 a share) for a market cap of $172.33 million plus the stock is down 16.9% since the start of the year, down 34.5% over the past year and down 41.6% over the past five years.

Cynosure, Inc. A developer and manufacturer of a broad array of light-based aesthetic and medical treatment systems, small cap Cynosure currently holds 37 US patents and markets over 14 different light based systems, representing advanced levels of solid-state, liquid and semiconductor laser technologies. At the end of July, Cynosure reported a 27% revenue increase to a record $50.1 million thanks to higher laser product sales across distribution channels plus $5.1 million in revenue from five days of sales attributable to the Palomar acquisition. Adjusted net income came in at $5.0 million with the company having $106 million in cash or cash equivalents and no debt at the end of the quarter. It should be noted that the Palomar Medical Technologies acquisition )for $294 million in cash and shares) means that Cynosure now has 20,000 laser hair removal machines in more than 100 countries plus the CEO was quoted as saying:

"Combining with Palomar complements our product portfolio and customer base, adding new product and service revenues, strengthening our global distribution network, creating new cross-selling opportunities and enhancing our intellectual property position."

Otherwise and back in May, Cynosure was added to the S&P SmallCap 600® Index. On Wednesday, Cynosure rose 0.39% to $23.08 (CYNO has a 52 week trading range of $21.14 to $30.20 a share) for a market cap of $514.80 million plus the stock is down 1.75% since the start of the year, down 12.7% over the past year and up 5.5% over the past five years.

Finally, here is a look at the share performance of Kythera Biopharmaceuticals verses the other small cap aesthetic treatment stocks:

As you can see from the above performance, its been a rather mixed performance for investors with Kythera Biopharmaceuticals and Cynosure being winners while Zeltiq Aesthetics and Solta Medical have been losers.

Home Prices Rise in July but at Slower Pace

Case shiller home price index housing marketSteven Senne/AP WASHINGTON -- U.S. home prices rose 12.4 percent in July compared with a year ago, the most since February 2006. An increase in sales on a limited supply of available homes drove the gains. The Standard &Poor's/Case-Shiller 20-city home price index reported Tuesday improved from June, when it rose 12.1 percent from a year ago. And all 20 cities posted gains in July from the previous month and compared with a year ago. Still, the month-over-month price gains shrank in 15 cities in July compared with the previous month, indicating prices may be peaking. And the month-over-month gains in the 20-city price index have slowed for three straight months. Stan Humphries, chief economist for real estate data provider Zillow, said home price should continue to rise but at a slower pace. Mortgage rates have increased more than a full percentage point since May. And more homes are being built. That should ease supply constraints that have inflated prices in some markets. "This ongoing moderation is good for the market overall," Humphries said. Home prices soared 27.5 percent in Las Vegas from a year earlier, the largest gain. San Francisco's 24.8 percent jump was the second largest and the biggest yearly return for that city since March 2001. The index covers roughly half of U.S. homes. It measures prices compared with those in January 2000 and creates a three-month moving average. The July figures are the latest available. They are not adjusted for seasonal variations, so the monthly gains reflect more buying activity over the summer. Since bottoming out in March 2012, home prices have rebounded about 21 percent. They remain about 22 percent below the peak reached in July 2006. The housing market has been recovering over the past year, helped by steady job growth, low mortgage rates and relatively low prices. Sales of previously occupied homes rose in August to a seasonally adjusted 5.5 million annual pace, according to the National Association of Realtors. That's a healthy level and the highest in more than six years. But the realtors' group cautioned that the August pace could represent a temporary peak. The gain reflected closings and largely occurred because many buyers rushed to lock in mortgage rates in June and July before they increased further. The Realtors said buyer traffic dropped off noticeably in August, likely reflecting the higher rates. The average rate on a 30-year fixed mortgage was 4.5 percent last week. That's near a two-year high. It's still low by historical standards. Rates rose in May after Chairman Ben Bernanke suggested the Federal Reserve could slow its bond purchase program before the end of the year. But the Fed surprised markets last week by deciding against reducing the $85-billion-a-month in bond buys, which have kept longer-term interest rates low. The Fed said a key reason for its decision was the sharp increase in mortgage rates and other interest rates. The Fed's decision could ease rates temporarily, although many economists expect the Fed will ultimately slow the purchases, perhaps as early as December. Rates would likely rise after that.

Top Undervalued Companies To Invest In Right Now

As more industrial companies report, what had originally looked like a pretty good quarter is looking increasingly mixed. While companies with exposure to aerospace, automotive, and energy markets are generally doing pretty well (including Honeywell (NYSE:HON), General Electric (NYSE:GE), and Dover (NYSE:DOV)), businesses leveraged to industrial and utility markets are seeing shakier results.

In the case of ABB (NYSE:ABB), the problem isn't so much about the quarter that is in the books, but rather the company's double-digit decline in orders. Although it seems that management believes this is mostly a timing issue, weakness in the peer group and declines in markets like mining and robotics could be more problematic. I'm still fundamentally bullish on ABB shares, and it's a rare undervalued industrial stock, but it may take a couple of quarters for the Street to feel comfortable with the story again.

Q2 Good Or Bad, Depending On Where You Look
ABB had a good news/bad news report for the second quarter, with most of the bad news weighted towards where analysts and investors put the most emphasis (orders and margins).

SEE: Conglomerates: Risky Proposition?

Revenue rose 6% as reported, or 2% on an organic basis, which was good for a very small beat relative to the average estimate. Growth was led by the power businesses (Products up 6%, Systems up 5%, Low Voltage flat), while automation was mixed as discrete fell 1% and process rose 4%.

Operating income rose a little less than 5% on an adjusted basis, with operating margins holding more or less steady. Operational EBITDA, the preferred profitability metric for this company, rose 6% and just slightly exceed expectations as margins barely improved (15.2% versus 15.1%) from last year. Profitability in the power businesses improved significantly, while automation profits declined.

Orders Will Overshadow Results
If that were all to say about ABB, I think you could make the case that ABB is doing pretty well in a market where competitors like Honeywell, Emerson (NYSE:EMR), Siemens (NYSE:SI), and Alstom are struggling to show much growth in these markets. Unfortunately, the news on orders will definitely overshadow second quarter results.

Top Undervalued Companies To Invest In Right Now: Tupperware Corporation(TUP)

Tupperware Brands Corporation operates as a direct seller of various products across a range of brands and categories through an independent sales force. The company engages in the manufacture and sale of kitchen and home products, and beauty and personal care products. It offers preparation, storage, and serving solutions for the kitchen and home, as well as kitchen cookware and tools, children?s educational toys, microwave products, and gifts under the Tupperware brand name primarily in Europe, Africa, the Middle East, the Asia Pacific, and North America. The company provides beauty and personal care products, which include skin care products, cosmetics, bath and body care, toiletries, fragrances, nutritional products, apparel, and related products principally in Mexico, South Africa, the Philippines, Australia, and Uruguay. It offers beauty and personal care products under the Armand Dupree, Avroy Shlain, BeautiControl, Fuller, NaturCare, Nutrimetics, Nuvo, and Swissgar de brand names. The company sells its Tupperware products directly to distributors, directors, managers, and dealers; and beauty products primarily through consultants and directors. As of December 26, 2009, the Tupperware distribution system had approximately 1,800 distributors, 61,300 managers, and 1.3 million dealers; and the sales force representing the Beauty businesses approximately 1.1 million. The company was formerly known as Tupperware Corporation and changed its name to Tupperware Brands Corporation in December 2005. The company was founded in 1996 and is headquartered in Orlando, Florida.

Top Undervalued Companies To Invest In Right Now: Schlumberger N.V.(SLB)

Schlumberger Limited, together with its subsidiaries, supplies technology, integrated project management, and information solutions to the oil and gas exploration and production industries worldwide. The company?s Oilfield Services segment provides exploration and production services; wireline technology that offers open-hole and cased-hole services; supplies engineering support, directional-drilling, measurement-while-drilling, and logging-while-drilling services; and testing services. This segment also offers well services; supplies well completion services and equipment; artificial lift; data and consulting services; geo services; and information solutions, such as consulting, software, information management system, and IT infrastructure services that support oil and gas industry. Its WesternGeco segment provides reservoir imaging, monitoring, and development services; and operates data processing centers and multiclient seismic library. This segment also offers variou s services include 3D and time-lapse (4D) seismic surveys to multi-component surveys for delineating prospects and reservoir management. The company?s M-I SWACO segment supplies drilling fluid systems to improve drilling performance; fluid systems and specialty tools to optimize wellbore productivity; production technology solutions to maximize production rates; and environmental solutions that manages waste volumes generated in drilling and production operations. Its Smith Oilfield segment designs, manufactures, and markets drill bits and borehole enlargement tools; and supplies drilling tools and services, tubular, completion services, and other related downhole solutions. The company?s Distribution segment markets pipes, valves, and fittings, as well as mill, safety, and other maintenance products. This segment also provides warehouse management, vendor integration, and inventory management services. Schlumberger Limited was founded in 1927 and is based in Houston, Texas.

Advisors' Opinion:
  • [By Dr. Kent Moors]

    That's why some of the biggest OFS providers - like Schlumberger (NYSE: SLB), Halliburton (NYSE: HAL) and Weatherford International (NYSE: WFT) - have been buying up oil and gas equipment companies.

Hot Energy Companies To Invest In Right Now: Dollar Tree Inc.(DLTR)

Dollar Tree, Inc. operates discount variety stores in the United States and Canada. Its stores offer merchandise primarily at the fixed price of $1.00. The company operates its stores under the names of Dollar Tree, Deal$, Dollar Tree Deal$, Dollar Giant, and Dollar Bills. Its stores offer consumable merchandise, including candy and food, and health and beauty care, as well as household consumables, such as paper, plastics, household chemicals, in select stores, and frozen and refrigerated food; variety merchandise, which includes toys, durable housewares, gifts, party goods, greeting cards, softlines, and other items; and seasonal goods, such as Easter, Halloween, and Christmas merchandise. As of April 30, 2011, it operated 4,089 stores in 48 states and the District of Columbia, as well as 88 stores in Canada. The company was founded in 1986 and is based in Chesapeake, Virginia.

Advisors' Opinion:
  • [By Lawrence Meyers]

    The finance sector, as mentioned, can make money in many ways. The second-highest growth sector is expected to be consumer discretionary, with a 6.2% increase. When you look at earnings from luxury brands like Tiffany & Co. (TIF), and that the hotel sector continues to do very well, it suggests that those people who are in good financial shape are spending their money. Meanwhile, dollar players like Dollar Tree (DLTR) continue to perform very well, suggesting that folks with less money are spending it on cheaper items.

  • [By Lawrence Meyers]

    As a convenience store, it doesn’t have direct competition from�Dollar Tree (DLTR) or Family Dollar (FDO) because these dollar stores aren�� exclusively focused on food (and they have no gasoline or cigarette sales), and they��e targeted at the folks who are trying to save money over convenience, not vice versa. The convenience angle is another reason why�Walmart (WMT) and Costco (COST)�aren’t competitors, since those behemoths are about a total shopping experience.

  • [By Rising Dividend Investing]

    Falling Stock Correlation: What It Says About Consumer Spending

    As we mentioned in the Take Aways from the August 26th Investment Policy Committee meeting, the correlation index has been steadily declining. In 2008-09, macroeconomic events drove nearly every stock downwards. Specific sectors and stocks moved in tandem with one another. Today, stocks and sub-industries within each sector are performing very differently – which indicates a return to a more normal stock market environment.
    The Consumer Discretionary (also known as Consumer Cyclicals) sector is an example of an industry that has been rewarded for its fundamental success over the past 12 months. As a whole, the sector grew sales 6.1% and earnings 9.2% in the second quarter - much better than the 1.4% sales and 3.3% earnings growth of the S&P 500. While the overall sector did well in the second quarter, the table below shows how differently the 5 sub-categories of Consumer Discretionary performed:

    (click to enlarge)
    As we drill down even further, sub-categories of sub-sectors differ even more dramatically. Below is a snapshot of the Retailing sub-sector and its notable components:

    (click to enlarge)
    Specific stocks within each sub-category are varying in performance as well. General Merchandise retailers were significantly differentiated in the second quarter. Target’s (TGT) adjusted EPS were up 6.1% from 2012, while Dollar General (DG) and Dollar Tree’s (DLTR) earnings were up nearly 12% and 9%, respectively.
    The differences in sales and earnings growth amongst these different industries tell a story. The economy is not improving enough that people feel like they can let go and spend money on pure pleasures, but it is improving enough that they can afford to replace their cars and fix the doors on their houses. As these items wear out and need to be replaced, we expect the pent up demand will drive increased economic activity from cons

Top Undervalued Companies To Invest In Right Now: Caterpillar Inc.(CAT)

Caterpillar Inc. manufactures and sells construction and mining equipment, diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives worldwide. It operates through three lines of businesses: Machinery, Engines, and Financial Products. The Machinery business offers construction, mining, and forestry machinery, including track and wheel tractors, track and wheel loaders, pipelayers, motor graders, wheel tractor-scrapers, track and wheel excavators, backhoe loaders, log skidders, log loaders, off-highway trucks, articulated trucks, paving products, skid steer loaders, underground mining equipment, tunnel boring equipment, and related parts. It also manufactures diesel-electric locomotives; and manufactures and services rail-related products and logistics services for other companies. The Engines business provides diesel, heavy fuel, and natural gas reciprocating engines for Caterpillar machinery, electric power generation systems, marine, petrol eum, construction, industrial, agricultural, and other applications. It offers industrial turbines and turbine-related services for oil and gas, and power generation applications. This business also remanufactures Caterpillar engines, machines, and engine components; and offers remanufacturing services for other companies. The Financial Products business provides retail and wholesale financing alternatives for Caterpillar machinery and engines, solar gas turbines, and other equipment and marine vessels, as well as offers loans and various forms of insurance to customers and dealers. It also offers financing for vehicles, power generation facilities, and marine vessels. The company markets its products directly, as well as through its distribution centers, dealers, and distributors. It was formerly known as Caterpillar Tractor Co. and changed its name to Caterpillar Inc. in 1986. Caterpillar Inc. was founded in 1925 and is headquartered in Peoria, Illinois.

Advisors' Opinion:
  • [By Rebecca McClay]

    Building roads and bridges takes a lot of heavy equipment, and that's exactly what Caterpillar (CAT) makes. Whether a project needs backhoes, excavators, pavers or the articulated trucks to get asphalt and other building materials from one location to another, the Peoria, Ill., manufacturer is the industry leader both in the U.S. and abroad.

  • [By Shauna O'Brien]

    Bank of America/Merrill Lynch reported on Tuesday that it has cut its estimates on Caterpillar Inc. (CAT).

    The firm, which currently has a “Neutral” rating on CAT, has lowered estimates on the company through 2015. Analysts currently have a $88 price target on CAT, suggesting a 1% increase from the stock’s current price of $86.88.

    Caterpillar shares were mostly flat during Tuesday morning trading. The stock has been mostly flat YTD.

  • [By StreetAuthority]

    Gabriel Bouys, AFP/Getty ImagesBill Gates, Microsoft co-founder and co-chair of the Bill & Melinda Gates Foundation. $650 million is a lot of money -- even for Bill Gates. That's how much his investment firm has invested in what might be considered the best way to play China. It's not a software firm or even a computer hardware firm. It's mining giant Caterpillar (CAT). Gates started building a position in Caterpillar before the financial crisis, but he became a very aggressive buyer once the crisis hit and shares had fallen by half. Yet remarkably, Gates has kept on buying, even as shares steadily rebounded to previous peaks. But now that Caterpillar has come under pressure on concerns that China is slowing, is Gates locking in profits? No, he's been buying more, picking up another 500,000 shares in this year's second quarter. At current prices, his firm's stake of 10.76 million shares is worth a cool $650 million. The key question: Why does Gates continue to buy shares even after China's slowdown has signaled the potential end of a global commodities boom? After all, much of Caterpillar's growth in recent years has come from a strong surge in mining activity that uses the company's massive excavators. The simple answer is that Gates and his team of investment managers always focus on long-term winners and never buy or sell shares based on short-term economic shifts. We've seen him do it many times before. For example, even as Wall Street analysts focused on the near-term prospects for auto retailer AutoNation (AN), Gates saw an epic rebound coming, as I noted in this article. Shares of AutoNation have now risen 400 percent since early 2009. Caterpillar: The Long View

Weekly Guru Bargains Highlights

According to GuruFocus updates, these stocks have declined the most since Gurus have bought.

Macromill (3730): Down 53% Since Matthews Japan Fund Bought In the Quarter Ended on 2013-06-30 Matthews Japan Fund initiated holdings in during the quarter ended June 30. His purchase prices were between $537 and $1670, with an estimated average price of $1268.42. Since then the prices of Macromill Inc shares have declined by -53% from the estimated average. Matthews Japan Fund owned 574,600 shares of Macromill Inc as of the close of the second quarter.

Security Bank Corp (SECB): Down 26% Since Wasatch International Growth Bought In the Second Quarter
Wasatch International Growth added to his holdings in by 67.98% during the quarter ended June 30. His purchase prices were between $140 and $202.2, with an estimated average price of $181.84. Since then the prices of Security Bank Corp shares have declined by -26% from the estimated average. Wasatch International Growth owned 3,107,353 shares of Security Bank Corp as of the second quarter.

Potash Corporation of Saskatchewan, Inc. (POT): Down 21% Since Jean-Marie Eveillard Bought In the Quarter Ended on 2013-06-30 Jean-Marie Eveillard added to his holdings in Specialty Chemicals company Potash Corporation of Saskatchewan by 22.42% during the quarter ended June 30. His purchase prices were between $38.02 and $43.78, with an estimated average price of $40.86. Since then the prices of Potash Corporation of Saskatchewan shares have declined by -21% from the estimated average. Jean-Marie Eveillard owned 14,633,953 shares of Potash Corporation of Saskatchewan as of 2013Q2.

Potash Corporation Of Saskatchewan has a market cap of $27.97 billion; its shares were traded at around $32.24 with a P/E ratio of 12.47 and P/S ratio of 3.52. The dividend yield of Potash Corporation Of Saskatchewan stocks is 3.26%. Potash Corporation Of Saskatchewan had an annual average earnings growth of 34.3% over the past 10 years. GuruFocus rated Potash Corporation ! Of Saskatchewan the business predictability rank of 3-star.

Jean-Marie Eveillard owns 14,633,953 shares as of 06/30/2013, an increase of 22.42% from the previous quarter. This position accounts for 1.7% of the $32.18 billion portfolio of First Eagle Investment Management, LLC.

Director or Senior Officer of Insider or Subsidiar Brent Heimann, bought 6,000 shares of POT stock on Aug. 6 at the average price of 28.95. Brent Heimann, owns at least 23,087 shares after this. The price of the stock has increased by 11.36% since.

Calpine Corp (CPN): Down 27% Since Matthews Pacific Tiger Fund Bought In the Quarter Ended on 2013-06-30 Matthews Pacific Tiger Fund added to his holdings in Electricity company Calpine Corp by 96.26% during the quarter ended June 30. His purchase prices were between $41 and $104, with an estimated average price of $65.7. Since then the prices of Central Pattana Public Company Limited shares have declined by -27% from the estimated average. Matthews Pacific Tiger Fund owned 130,207,600 shares of Central Pattana Public Company Limited as of the second quarter.

Calpine Corp has a market cap of $8.57 billion; its shares were traded at around $19.51 with a P/E ratio of 26.18 and P/S ratio of 1.45.

John Burbank owns 2,093,756 shares as of June 30, an increase of 65.39% from the previous quarter. This position accounts for 1.5% of the $3.04 billion portfolio of Passport Capital. Jean-Marie Eveillard owns 1,000 shares as of June 30, a decrease of 99.93% of from the previous quarter. This position accounts for 0.0001% of the $32.18 billion portfolio of First Eagle Investment Management, LLC.

Director David C Merritt bought 10,000 shares of CPN stock on Aug. 19 at the average price of 18.69. David C Merritt owns at least 36,375 shares after this. The price of the stock has increased by 4.39% since.

Daiken Medical Co., Ltd. (7775): Down 47% Since Matthews Japan Fund Bought In the Quarter Ended on 2013-06-30 Matthews Japan Fund initiated holdings in! Electric! ity company during the quarter ended June 30. His purchase prices were between $1558 and $4970, with an estimated average price of $3632.45. Since then the prices of Daiken Medical Ltd. shares have declined by -47% from the estimated average. Matthews Japan Fund owned 70,000 shares of Daiken Medical Co., Ltd. as of June 30.
Related links:Jean-Marie EveillardThe business predictability rank of 3-star

Apple Can't Wow People, My Ass

NEW YORK (TheStreet) -- When Apple's (AAPL) Phil Schiller spewed Can't innovate any more, my ass at this year's Worldwide Developer's Conference, I came out against his defensiveness. Because, as I explained Monday morning at TheStreet, if you're not concerned about Apple's ability to innovate in a post-Steve Jobs world, they should be waiting for you at Bellevue with their oxygen masks.

(Go ahead, Google that fine piece of lyrical gold).

Schiller simply misplaced his anger. With iTunes Radio, Apple is absolutely not innovating; it's knocking off Pandora (P). And, while you can technically call it "innovation," the new Mac Pro computer, as incredible as it is, means little, if anything, in the consumer (or even business) marketplace. Certainly, you can make the case that Apple should and needs to do these things, but the Internet radio thing isn't innovative and the computer that could double as a generator is innovation in a vacuum.

I would much rather have seen Schiller level with people. Sort of like Tim Cook did when he said Apple will never make "crappy products." (My, what crude language out of the mouths of these Apple executives). Second link, first paragraph. The data's in there. The media is lying to you. Or, at the very least, it's not reporting a complete story. In the U.S. smartphone market, iOS is the only platform that gained market share in the most recent reporting period, according to comScore. Apple's down a couple percentage points as an OEM, but still miles ahead of No. 2 Samsung, even though it hasn't had a new phone in what feels like ages (until last week). The fact is that Apple doesn't need to wow consumers with iPhone. It has already accomplished that millions of times over. Luxury brands, particularly automakers such as BMW and Mercedes, don't have to keep wowing people. They have hooked a strong core of consumers who upgrade their motor vehicle every so often. The new 7-Series doesn't necessarily come with revolutionary enhancements; they're most always evolutionary. And, until Tesla Motors (TSLA) came along, there wasn't much meaningful challenge to that strategy. Not to say that BMW, Mercedes and others should stand still, but Tesla, as great as it is, remains a regional phenomenon. With this analogy, I don't mean to say Apple should stand still. Absolutely not. But it does not need to, nor should it make anything but incremental upgrades to its existing pipeline of best-selling iPhones and iPads. Even if a Tesla-equivalent came along in the smartphone world (#lolz to the notion that one exists), Apple should not change course. Unlike its competitors, Apple has hit it big -- they have products that stand the test of the upgrade cycle. Loads of folks who passed on the iPhone 5 are now free to pick up a 5s. And, next year, people like me, saddled with one year remaining on an iPhone 5 contract, will be able to pick up an iPhone 6, penalty-free. I'm not quite sure why so many people expect Apple to mess with a winner at the same time as the critics attempt to, disingenuously, brand it a loser. For the umpteenth time, Apple does need to step up its game. It needs to focus on keeping the halo effect alive. That will happen with a new product that complements what already exists, both inside and outside of Apple's wide-ranging ecosystem. Follow @rocco_thestreet --Written by Rocco Pendola in Santa Monica, Calif.

Before Buying OmniVision, Look Both Ways

NEW YORK (TheStreet) -- Since reporting fiscal first-quarter earnings results that disappointed the Street, shares of OmniVision (OVTI), which were already in a downtrend, have lost another 17%.

Understandably, OmniVision bulls insist that the stock is oversold, while "observers" are debating whether to take a closer "peek" at a possible turnaround candidate.

Although the valuation does look interesting here, I would be careful about catching -- what might prove to be -- a falling knife.

This is not the first time this company has taken some bruises. While OmniVision, which has a strong position in the image-sensor market, has benefited from its ties to Apple (AAPL), the company has also experienced some volatile price swings. After this recent selloff, it's anyone's guess where this stock is heading next, especially in light of what I believe was a decent quarter. First things first: Given the weakness we have seen in mobile handset shipments, that OmniVision was able to grow revenue by close to 45% year over year was pretty impressive. Plus, the fact that revenue advanced 11% sequentially amid a low ASP, or average selling price, environment was equally remarkable. Unfortunately though, OmniVision still didn't do enough to please the Street -- which had modeled for an extra 2% to 5% growth (according to some estimates). Now, for a little more context, consider that Qualcomm (QCOM), which is the leader among semiconductors in the mobile/wireless business, is coming off a quarter during which revenue advanced 35% year over year. In the same category, Broadcom (BRCM) just posted 7% revenue growth, which fell short of Street estimates by nearly 10%. Yet, neither Qualcomm nor Broadcom have seen their stocks erode to the degree of OmniVision. This is even though all three companies are dealing with the same fears of high-end mobile device saturation. By that logic, investors are betting that OmniVision's 17% decline in the stock was an overreaction. It very well may be. But there's one key difference. As has been the case for quite some time, OmniVision continues to suffer from weak leverage. Also, profitability hasn't always been strong, which explains the company's history of volatility.

Again this quarter, gross margins, which declined by almost 2% year over year, reminded analysts of just how competitive OmniVision's market has become. Not to mention, management didn't help matters by issuing guidance that was more than 7% below estimates, effectively confirming reasons for the panic.

Now, I do understand that management didn't want to set expectations too high and set the company up to fail. But it's worth asking if OmniVision's relationship with Apple is as strong as previously perceived?

To be fair, I don't have sufficient data to model how much revenue growth OmniVision should generate from Apple's recent launch of the iPhone 5S and the 5C. But looking back at OminiVision's fiscal second-quarter of 2013 (November quarter 2012), the company posted an almost 80% jump in revenue, helped (in part) by a 62% increase in device shipments. What I also know is that, OmniVision's second-quarter performance followed Apple's launch of the original iPhone 5 and the iPad mini last September.

But understand, I'm not suggesting that OmniVision is guaranteed to have a blowout quarter. Nor am I suggesting that management has no clue what it's doing. But I do see several catalysts to suspect that management may be low-balling guidance just a bit, especially if Apple announces a deal with China Mobile (CHL). The other thing to consider is that, Avago (AVGO), which is another Apple supplier, recently raised guidance -- presumably, in anticipation of better-than-expected demand from the iPhone launch. So far, both the iPhone 5S and 5C have received better-than-expected reviews, relative to the initial downbeat response by the Street. What this means is that there is no clear answer as to what OminiVision's management might be thinking. However, from a pure valuation play, I do see a possible bounce in the stock from the 17% decline. And if Apple does contribute to a recovery in ASPs, which would then dispel fears of high-end device saturation, OminiVision stock can head back toward the $18 to $20 range. But let me remind you of the volatile nature of this company. I would suggest you look both ways before crossing that bridge.

At the time of publication, the author was long AAPL.

Follow @saintssense

This article was written by an independent contributor, separate from TheStreet's regular news coverage.

Richard Saintvilus is a co-founder of StockSaints.com where he serves as CEO and editor-in-chief. After 20 years in the IT industry, including 5 years as a high school computer teacher, Saintvilus decided his second act would be as a stock analyst - bringing logic from an investor's point of view. His goal is to remove the complicated aspect of investing and present it to readers in a way that makes sense. His background in engineering has provided him with strong analytical skills. That, along with 15 years of trading and investing, has given him the tools needed to assess equities and appraise value. Richard is a Warren Buffett disciple who bases investment decisions on the quality of a company's management, growth aspects, return on equity, and price-to-earnings ratio. His work has been featured on CNBC, Yahoo! Finance, MSN Money, Forbes, Motley Fool and numerous other outlets. Follow @saintssense